Literature DB >> 21413054

Calibration of prior variance in the Bayesian continual reassessment method.

Shing M Lee1, Ying Kuen Cheung.   

Abstract

The continual reassessment method (CRM) is an adaptive model-based design used to estimate the maximum tolerated dose in phase I clinical trials. Asymptotically, the method has been shown to select the correct dose given that certain conditions are satisfied. When sample size is small, specifying a reasonable model is important. While an algorithm has been proposed for the calibration of the initial guesses of the probabilities of toxicity, the calibration of the prior distribution of the parameter for the Bayesian CRM has not been addressed. In this paper, we introduce the concept of least informative prior variance for a normal prior distribution. We also propose two systematic approaches to jointly calibrate the prior variance and the initial guesses of the probability of toxicity at each dose. The proposed calibration approaches are compared with existing approaches in the context of two examples via simulations. The new approaches and the previously proposed methods yield very similar results since the latter used appropriate vague priors. However, the new approaches yield a smaller interval of toxicity probabilities in which a neighboring dose may be selected.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21413054      PMCID: PMC3129459          DOI: 10.1002/sim.4139

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  7 in total

1.  A simple technique to evaluate model sensitivity in the continual reassessment method.

Authors:  Ying Kuen Cheung; Rick Chappell
Journal:  Biometrics       Date:  2002-09       Impact factor: 2.571

2.  A comparison of model choices for the Continual Reassessment Method in phase I cancer trials.

Authors:  X Paoletti; A Kramar
Journal:  Stat Med       Date:  2009-10-30       Impact factor: 2.373

3.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

4.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

5.  The continual reassessment method in cancer phase I clinical trials: a simulation study.

Authors:  S Chevret
Journal:  Stat Med       Date:  1993-06-30       Impact factor: 2.373

6.  Sequential designs for phase I clinical trials with late-onset toxicities.

Authors:  Y K Cheung; R Chappell
Journal:  Biometrics       Date:  2000-12       Impact factor: 2.571

7.  Model calibration in the continual reassessment method.

Authors:  Shing M Lee
Journal:  Clin Trials       Date:  2009-06       Impact factor: 2.486

  7 in total
  20 in total

1.  Flexible Phase I-II design for partially ordered regimens with application to therapeutic cancer vaccines.

Authors:  Nolan A Wages; Craig L Slingluff
Journal:  Stat Biosci       Date:  2019-06-04

2.  Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?

Authors:  Alexia Iasonos; Mithat Gönen; George J Bosl
Journal:  J Clin Oncol       Date:  2015-05-04       Impact factor: 44.544

3.  CRM2DIM: A SAS macro for implementing the dual-agent Bayesian continual reassessment method.

Authors:  Mohamed Amine Bayar; Anastasia Ivanova; Gwénaël Le Teuff
Journal:  Comput Methods Programs Biomed       Date:  2019-05-06       Impact factor: 5.428

4.  Sequential multiple assignment randomized trial (SMART) with adaptive randomization for quality improvement in depression treatment program.

Authors:  Ying Kuen Cheung; Bibhas Chakraborty; Karina W Davidson
Journal:  Biometrics       Date:  2014-10-29       Impact factor: 2.571

5.  A Generalized Continual Reassessment Method for Two-Agent Phase I Trials.

Authors:  Thomas M Braun; Nan Jia
Journal:  Stat Biopharm Res       Date:  2013-01-01       Impact factor: 1.452

6.  Evaluation of irrational dose assignment definitions using the continual reassessment method.

Authors:  Nolan A Wages; Evan Bagley
Journal:  Clin Trials       Date:  2019-09-23       Impact factor: 2.486

7.  Sample size formulae for the Bayesian continual reassessment method.

Authors:  Ying Kuen Cheung
Journal:  Clin Trials       Date:  2013-08-21       Impact factor: 2.486

8.  Adaptive prior variance calibration in the Bayesian continual reassessment method.

Authors:  Jin Zhang; Thomas M Braun; Jeremy M G Taylor
Journal:  Stat Med       Date:  2012-09-17       Impact factor: 2.373

9.  A Phase I/II trial design when response is unobserved in subjects with dose-limiting toxicity.

Authors:  Thomas M Braun; Shan Kang; Jeremy Mg Taylor
Journal:  Stat Methods Med Res       Date:  2012-11-01       Impact factor: 3.021

10.  Design of implementation studies for quality improvement programs: an effectiveness-cost-effectiveness framework.

Authors:  Ken Cheung; Naihua Duan
Journal:  Am J Public Health       Date:  2013-11-14       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.